27 Dec 2023 07:00
e-therapeutics plc
("e-therapeutics" or the "Company")
Update on OTCQX Market Listing
London, UK, 27 December 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announces that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX").
The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders.
The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.
Enquiries:
e-therapeutics plc |
|
Ali Mortazavi, CEO Timothy Bretherton, CFO
| Tel: +44 (0)20 4551 8888 www.etherapeutics.co.uk |
SP Angel Corporate Finance LLP | Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker |
|
Matthew Johnson/Harry Davies-Ball (Corporate Finance) |
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.
ETX's proprietary HepNet? platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises, and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.
GalOmic?, ETX's proprietary RNAi platform, enables targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNet?. The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmic? constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class RNAi candidates across a variety of therapeutic areas with high unmet need, including preclinical programs in cardiometabolic and metabolic diseases, haemophilia, and other undisclosed indications. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.
The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.